ARA-290, 10mg

Mechanism of Action

ARA-290 (Cibinetide) is an 11-amino-acid synthetic peptide engineered from the three-dimensional structure of erythropoietin (EPO). Unlike full-length EPO, ARA-290 was designed to selectively interact with the Innate Repair Receptor (IRR) while exhibiting minimal activity at the classical erythropoietin receptor responsible for red blood cell production.

Receptor Selectivity

Erythropoietin interacts with two biologically distinct receptor complexes.

The classical erythropoietin receptor (EPOR homodimer) is expressed primarily on erythroid progenitor cells within the bone marrow. Activation of this receptor initiates intracellular signaling through pathways such as JAK2 and STAT5, leading to erythropoiesis.

In contrast, the Innate Repair Receptor (IRR) is a heteromeric receptor complex composed of the erythropoietin receptor (EPOR) and the β-common receptor (CD131). This receptor has been identified on numerous cell types, including neurons, Schwann cells, endothelial cells, immune cells, renal tubular cells, fibroblasts, and cardiomyocytes. Activation of the IRR has been investigated for its role in regulating cellular stress responses, inflammatory signaling, and tissue repair processes.

Design of ARA-290

ARA-290 corresponds to an eleven-amino-acid sequence derived from the surface of helix B within the erythropoietin molecule. Structural studies suggest this region participates in interactions with the β-common receptor component of the Innate Repair Receptor while exhibiting limited affinity for the classical erythropoietin receptor.

This receptor selectivity allows ARA-290 to serve as a research model for studying tissue-protective signaling pathways independently of erythropoiesis.

Intracellular Signaling

Activation of the Innate Repair Receptor has been associated with several intracellular signaling pathways that regulate cellular homeostasis, including:

• JAK2/STAT3 signaling, involved in cellular stress responses and regulation of inflammatory gene expression.
• PI3K/Akt signaling, associated with cell survival, metabolic regulation, and resistance to cellular stress.
• MAPK (ERK and p38) pathways, which participate in cellular proliferation, differentiation, and tissue remodeling.
• NF-κB modulation, a pathway involved in regulating inflammatory cytokine production and immune signaling.

These signaling cascades remain active areas of investigation in studies examining tissue injury, inflammation, and regenerative biology.

Immune Signaling Research

Experimental studies have reported that activation of the Innate Repair Receptor may influence multiple aspects of innate immune function. Areas of investigation include:

• Regulation of pro-inflammatory cytokine expression
• Modulation of anti-inflammatory signaling pathways
• Changes in macrophage activation states
• Alterations in neutrophil recruitment during tissue injury
• Maintenance of immune homeostasis during inflammatory responses

These findings continue to be evaluated in models of inflammatory disease and tissue repair.

Nervous System Research

ARA-290 has been widely investigated in laboratory models involving the peripheral and central nervous systems. Published studies have examined its effects on:

• Cellular responses to metabolic and oxidative stress
• Schwann cell biology
• Peripheral axonal regeneration
• Small fiber nerve morphology
• Neuroimmune interactions
• Microglial activation
• Mitochondrial function in neural tissue

These investigations have contributed to ongoing research into mechanisms of nerve repair and neuroinflammation.

Microvascular Biology

The Innate Repair Receptor is also expressed on vascular endothelial cells, making ARA-290 a useful research compound for studying vascular biology. Experimental investigations have explored its influence on:

• Endothelial signaling pathways
• Nitric oxide synthase activity
• Microvascular perfusion
• Endothelial inflammatory responses
• Tissue responses following ischemic injury

Tissue Repair Research

Preclinical studies have investigated ARA-290 in experimental models of tissue injury, including ischemia-reperfusion, dermal wound healing, and inflammatory injury. Research has focused on its effects on:

• Cellular inflammatory responses
• Granulation tissue development
• Re-epithelialization
• Extracellular matrix remodeling
• Angiogenic signaling
• Fibrotic remodeling following tissue injury

Cardiac Research

Experimental cardiovascular models have also examined activation of the Innate Repair Receptor following ischemic injury. Current research has investigated cellular survival pathways, inflammatory signaling, myocardial remodeling, and functional recovery in preclinical systems.

ARA-290 is not approved by the U.S. Food and Drug Administration for human use. Its safety, efficacy, and pharmacological profile have not been established in approved FDA clinical trials. This compound is intended strictly for laboratory research purposes and is not for human or veterinary use.